Immune Design Reports Increased Overall Response Rate and Longer Progression Free Survival of Patients with Follicular Lymphoma Treated in a Randomized Trial with a Combination Regimen of G100 and Pembrolizumab
02 déc. 2018 12h00 HE
|
Immune Design Corp.
Overall Response Rate (ORR) of 46% in Patients Receiving the Combination TLR4 Biomarker Continued to Show Higher Response Rate for Patients with High TLR4 Expression (71% ORR) Long-term Follow Up...
Immune Design to Present at Piper Jaffray 30th Annual Healthcare Conference
20 nov. 2018 08h00 HE
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced...
Immune Design to Present at Jefferies 2018 London Healthcare Conference
09 nov. 2018 08h00 HE
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today that Carlos...
Immune Design Reports Third Quarter 2018 Financial Results and Provides Corporate Update
06 nov. 2018 16h01 HE
|
Immune Design Corp.
Conference call at 1:30 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation...
Immune Design Announces Multiple G100 Presentations at the Society for Immunotherapy of Cancer Meeting (SITC) Annual Meeting
06 nov. 2018 08h01 HE
|
Immune Design Corp.
New data further support G100’s broad potential in hematological malignancies and solid tumors SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:...
Immune Design to Report Third Quarter 2018 Financial Results and Provide Corporate Update
30 oct. 2018 08h00 HE
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it...
Immune Design Announces Program Updates & Portfolio Prioritization for G100 and CMB305
11 oct. 2018 16h01 HE
|
Immune Design Corp.
G100 development to accelerate in follicular lymphoma and beyondCMB305 to be deprioritized to support focus on G100Cash runway extended into 2021Conference call at 2:00 pm Pacific today SEATTLE and...
Immune Design to Present at Upcoming September Investor Conferences
30 août 2018 08h00 HE
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on novel therapies in oncology, today announced that senior...
Immune Design Reports Second Quarter 2018 Financial Results and Provides Corporate Update
01 août 2018 16h01 HE
|
Immune Design Corp.
G100 advancing to late-stage development following FDA feedbackConference call at 1:30 pm Pacific today SEATTLE, WA and SOUTH SAN FRANCISCO, CA, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Immune Design...
Immune Design to Report Second Quarter 2018 Financial Results and Provide Corporate Update
25 juil. 2018 08h00 HE
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., July 25, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced...